A Novel Way to Destroy Difficult-to-Treat Cancer Cells?
Professor Peter's team has now developed a new imaging and platelet targeting chemotherapy agent for the early detection and treatment of cancers.
An unexpected finding in preclinical platelet studies by Baker Institute researchers could provide a novel approach to targeting and destroying difficult-to-treat cancer cells, providing new therapeutic options for a range of cancers.
This latest finding, published in the journal Theranostics, was discovered while studying activated platelets in the setting of heart disease and may now prove useful for delivering targeted treatment to cancer cells without major side effects.
Early detection of cancer is crucial for successful therapy. However, some cancer types do not have specific cancer surface markers that can be used to detect them and even the same cancer type can exhibit different properties in different patients.
Professor Karlheinz Peter, Deputy Director of Basic and Translational Science at the Baker Heart and Diabetes Institute has been working for many years with platelets, which are small blood cells in the circulation that mainly promote blood clotting (e.g. platelets are the main perpetrator of a heart attack) and prevent us from bleeding when we are injured. In his recent experiments, he observed that platelets and more specifically, 'activated platelets' accumulate in the area surrounding a wide range at tumor types.
Based on this observation, Prof Peter’s PhD student May Lin Yap has now developed a new imaging and platelet targeting chemotherapy drug for the early detection and treatment of cancers. “We have shown that we can image activated platelets to detect tumors with clinically available imaging technologies such as ultrasound and PET/CT.”
“This unique approach holds great promise both for the diagnosis and therapy of a broad range of tumors. It provides a new treatment option particularly for difficult to treat cancer types that lack specific markers for therapy with conventional chemotherapy such as breast cancer etc.…” said Prof Karlheinz.
“This activated platelet targeted chemotherapy approach also provides the means to deliver high concentrations of chemotherapy specifically to tumor cells whilst minimizing side effects and preventing tumor growth.”
“This highly promising and unexpected discovery with immense importance for cancer diagnosis and therapy emerged from years of research on the function of platelets in heart disease. It is a good example of the importance of funding in basic research which often produces unexpected but highly relevant discoveries that ultimately will provide benefit for patients.”
His team has now patented the drug and is looking for funding to test in large-scale clinical studies.
This article has been republished from materials provided by Baker Institute. Note: material may have been edited for length and content. For further information, please contact the cited source.
Reference: May Lin Yap, et al. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. Theranostics. (2019) 9(4):1154-1169. doi:10.7150/thno.29146
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.
In a strategic search, scientists created and screened a library of 45,000 new compounds containing chemical elements of widely used immune system suppressants, and say they found one that may prevent reperfusion injury, a tissue-damaging and common complication of surgery, heart attack and stroke.READ MORE